Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data

Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data


Sopa Images | Lightrocket | Getty Images

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data.

The company’s two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, providing a potential pill-based alternative to Novo Nordisk’s Wegovy and Eli Lilly‘s Zepbound weight loss injections.

“We are fast-tracking the clinical development of our obesity portfolio with the aim to bring these medications to patients faster than anticipated,” the spokesperson told CNBC via email.

The company did not reveal its new timeline, saying it would provide an update “when appropriate.” However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm’s first obesity drug could come to market “significantly faster than people are expecting,” potentially by 2028.

Roche Pharmaceuticals CEO Teresa Graham previously told CNBC in December that she expected the company would be able to bring the products to market from 2030 onwards.

Roche’s CT-388 drug is now entering phase two trials after results published in May pointed to its efficacy in helping patients with obesity lose 18.8% of their weight after 24 weeks relative to those who received a placebo.

The company’s experimental once-daily pill CT-996 will enter phase two tests next year after trials earlier this month showed that it resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without Type 2 diabetes.

Both CT-388 and CT-996 were acquired as part of Roche’s purchase of U.S. biotech company Carmot Therapeutics, which completed in January.

The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Roche's weight loss adjacent drugs will boost its competitiveness, CEO says

“We have a number of things in our pipeline that really can differentiate us from other players,” Schinecker told CNBC’s “Squawk Box Europe.”

“We do believe we have two next generation GLP-1/GIPs that have a best in disease potential,” he said of the obesity drugs.

“We also have a number of different medicines in our own portfolio that we can combine with [obesity drugs],” he added, highlighting GYM329 as an example of a drug which counters muscle loss, a key side effect of weight loss.



Source

Paris Saint-Germain routs Inter Milan to win the Champions League for the first time
World

Paris Saint-Germain routs Inter Milan to win the Champions League for the first time

Paris St Germain’s Ousmane Dembele. Dylan Martinez | Reuters Paris Saint-Germain, Champions League winner. At long last the club that was transformed by Qatari billions and bought and sold a succession of the world’s greatest players in an extravagant bid to get to the top has its hands on the big one. European club soccer’s […]

Read More
Hamas seeks amendments to the U.S. ceasefire proposal for Gaza
World

Hamas seeks amendments to the U.S. ceasefire proposal for Gaza

A general view of destruction in North Gaza, as seen from the Israeli side of the Israel-Gaza border, on May 17, 2025. Amir Cohen | Reuters Hamas is seeking amendments to the latest U.S. ceasefire proposal for Gaza, a senior official with the group told The Associated Press on Saturday, as hungry Palestinians in Gaza […]

Read More
Couple bought a homestead for 0,000, spent ,000 on DIY renovations: Their No. 1 takeaway after a year on the land
World

Couple bought a homestead for $390,000, spent $13,000 on DIY renovations: Their No. 1 takeaway after a year on the land

In 2023, Sophie Hilaire Goldie, 37, and Rocky Goldie, 50, had just finished converting a friend’s Home Depot shed into a tiny home and were ready to start looking for their own place together. “If it wasn’t for meeting her, I probably would have ended up in a little shack,” Rocky tells CNBC Make It. […]

Read More